https://orcid.org/0000-0002-3878-8820
Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Catherine Rowan, Ryan Ungaro, Saurabh Mehandru & Jean-Frederic Colombel. (2022) An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis. Expert Opinion on Pharmacotherapy 23:8, pages 893-904.
Read now
Read now
Roni Aoun & Stephen Hanauer. (2022) A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis. Expert Review of Gastroenterology & Hepatology 16:5, pages 411-423.
Read now
Read now
Articles from other publishers (11)
Nathaniel A. Cohen, David Choi, Tenzin Choden, Noa Krugliak Cleveland, Russell D. Cohen & David T. Rubin. (2023) Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center. Clinical Gastroenterology and Hepatology 21:9, pages 2407-2409.e2.
Crossref
Crossref
Vincenzo Carlomagno, Massimiliano Mirabella & Matteo Lucchini. (2023) Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review. Bioengineering 10:7, pages 848.
Crossref
Crossref
Panagiotis Theodosis-Nobelos & Eleni A. Rekka. (2022) Efforts Towards Repurposing of Antioxidant Drugs and Active Compounds for Multiple Sclerosis Control. Neurochemical Research 48:3, pages 725-744.
Crossref
Crossref
Caroline Ruetsch-Chelli, Darin T. Okuda, Fanny Rocher, Sophie Tartare-Deckert, Marcel Deckert & Christine Lebrun-Frenay. (2022) Sphingosine-1 Phosphate Receptor Modulators Increase In Vitro Melanoma Cell Line Proliferation at Therapeutic Doses Used in Patients with Multiple Sclerosis. Neurology and Therapy 12:1, pages 289-302.
Crossref
Crossref
Marianna G. Rispoli, Maria D’Apolito, Valeria Pozzilli & Valentina Tomassini. 2023. Precision Medicine in Neurodegenerative Disorders, Part II. Precision Medicine in Neurodegenerative Disorders, Part II
293
311
.
Ramya Talanki Manjunatha, Salma Habib, Sai Lahari Sangaraju, Daniela Yepez & Xavier A Grandes. (2022) Multiple Sclerosis: Therapeutic Strategies on the Horizon. Cureus.
Crossref
Crossref
Leiye Yu, Licong He, Bing Gan, Rujuan Ti, Qingjie Xiao, Xin Yang, Hongli Hu, Lizhe Zhu, Sheng Wang & Ruobing Ren. (2022) Structural insights into sphingosine-1-phosphate receptor activation. Proceedings of the National Academy of Sciences 119:16.
Crossref
Crossref
Anna Kofla-Dłubacz, Katarzyna Akutko, Elżbieta Krzesiek, Tatiana Jamer, Joanna Braksator, Paula Grębska, Tomasz Pytrus & Andrzej Stawarski. (2022) Selective Forms of Therapy in the Treatment of Inflammatory Bowel Diseases. Journal of Clinical Medicine 11:4, pages 994.
Crossref
Crossref
Panfeng Fu, Ramaswamy Ramchandran, Steven M. Dudek, Narasimham L. Parinandi & Viswanathan Natarajan. 2022. Cardiovascular Signaling in Health and Disease. Cardiovascular Signaling in Health and Disease
445
484
.
Lindsey Sattler, Stephen B Hanauer & Lisa Malter. (2021) Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Current Gastroenterology Reports 23:12.
Crossref
Crossref
Saad A. Khan, Kayla F. Goliwas & Jessy S. Deshane. (2021) Sphingolipids in Lung Pathology in the Coronavirus Disease Era: A Review of Sphingolipid Involvement in the Pathogenesis of Lung Damage. Frontiers in Physiology 12.
Crossref
Crossref